June 10, 2022
On June 10, 2022, Numinus Wellness Inc. (“Numinus”) (TSX: NUMI; OTCQX: NUMIF) announced the completion of its acquisition of Novamind Inc. (“Novamind”) by way of a plan of arrangement, following Novamind’s receipt of a final order from the BC Supreme Court. As a result of the acquisition, Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine and psychedelic-assisted therapies.
Miller Thomson acted as securities counsel to Numinus in the transaction with a team led by Alexander Lalka (M&A/Securities) and included Thomas Ghag (M&A/Securities) and Ian Polisuk (M&A/Securities).